Drug Interaction Directory

Combining escitalopram and citalopram is pharmacologically redundant and doubles the QT-prolongation risk.

Combining a beta-blocker with verapamil can cause severe bradycardia, heart block, and cardiac arrest.

The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may exhibit decreased level of consciousness, hypoventilation, bradycardia, hypotension, and miosis. These effects can be life-threatening and require immediate medical intervention.

The combination of tramadol and alprazolam can lead to profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, hypotension, and psychomotor impairment. This interaction significantly increases the risk of accidental overdose and life-threatening respiratory events.

This combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased respiratory rate, shallow breathing, hypoxemia, unresponsiveness, and difficulty arousing.

The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may exhibit decreased level of consciousness, hypoventilation, pinpoint pupils, and hypotension.

Patients may experience profound sedation, respiratory depression (including apnea), hypotension, psychomotor impairment, coma, and death. The combination significantly increases the risk of accidental overdose and life-threatening adverse events. Impaired cognitive function and motor coordination can also increase the risk of falls and other injuries.

Concomitant use can cause severe respiratory depression, profound sedation, hypotension, psychomotor impairment, coma, and death. Patients may exhibit decreased level of consciousness, bradycardia, hypoventilation, and cyanosis.

Patients may experience severe respiratory depression, potentially leading to respiratory arrest, hypoxia, and death. Other clinical effects include profound sedation, somnolence, coma, hypotension, psychomotor impairment, and increased risk of accidental overdose or injury.

Concomitant use can lead to profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, hypotension, and psychomotor impairment. Even at usual doses, the combination can be life-threatening.

The combination significantly increases the risk of profound sedation, respiratory depression, coma, and death. Patients may experience extreme drowsiness, confusion, dizziness, slowed or difficult breathing, and unresponsiveness.

The primary clinical effects include profound sedation, respiratory depression (leading to hypoventilation and apnea), hypotension, and psychomotor impairment. This can rapidly progress to coma and death due to respiratory arrest, particularly in opioid-naïve individuals or those with underlying respiratory conditions.

This combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may exhibit decreased respiratory rate and depth, hypoxemia, somnolence, confusion, and impaired psychomotor function. The effects can be particularly pronounced in opioid-naive individuals or those with underlying respiratory conditions.

The interaction can manifest as severe sedation, profound respiratory depression, coma, and death. Patients may experience decreased level of consciousness, bradycardia, hypotension, and hypoxia. These effects can be rapid in onset and life-threatening.

This interaction leads to profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, and hypotension. The risk of overdose and fatal outcomes is significantly increased.

The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, hypoxia, and hypotension. Psychomotor impairment and an increased risk of falls are also common.

The concurrent use of morphine and temazepam significantly increases the risk of severe adverse effects including profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, hypotension, and psychomotor impairment. This combination can lead to life-threatening respiratory insufficiency.

Concomitant use significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, and hypotension. This interaction poses a life-threatening risk.

The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, and hypotension. These effects can be life-threatening and require immediate medical intervention.

The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may exhibit slowed or shallow breathing, extreme drowsiness, unresponsiveness, and hypoxemia. This interaction can rapidly progress to life-threatening respiratory arrest.

The combination significantly increases the risk of profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, and hypotension. This interaction can be life-threatening due to the synergistic depressant effects on the respiratory drive.

This combination significantly increases the risk of severe respiratory depression, profound sedation, hypotension, psychomotor impairment, coma, and death. Patients may experience decreased respiratory rate, shallow breathing, extreme drowsiness, confusion, and unresponsiveness.

The concurrent use of codeine and chlordiazepoxide can lead to profound sedation, respiratory depression, coma, and death. Patients may experience dizziness, confusion, psychomotor impairment, and hypotension. The risk is heightened in patients with pre-existing respiratory conditions, the elderly, and those receiving higher doses of either medication.

The combination can lead to profound sedation, respiratory depression (decreased respiratory rate and depth), coma, and death. Patients may experience extreme drowsiness, confusion, dizziness, and difficulty breathing. This interaction significantly impairs psychomotor function and decision-making.

Concomitant use significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased respiratory rate, shallow breathing, hypoxemia, unresponsiveness, and circulatory collapse.

Concomitant use can lead to severe adverse effects including profound sedation, respiratory depression, coma, and death. Patients may exhibit decreased level of consciousness, hypoventilation, hypoxia, and hypotension.

Concomitant use significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, bradycardia, hypotension, and hypoventilation.

This combination significantly increases the risk of severe respiratory depression, profound sedation, hypotension, psychomotor impairment, coma, and death. Patients may experience decreased level of consciousness, bradycardia, and hypoxemia.

The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased respiratory rate, hypoventilation, hypoxia, hypotension, and impaired mental status. The onset of these effects can be rapid and life-threatening.

Patients may experience severe respiratory depression, profound sedation, hypotension, psychomotor impairment, coma, and death. Even at therapeutic doses, the combination can lead to life-threatening respiratory insufficiency and altered mental status. The risk is heightened in opioid-naive individuals or those with underlying respiratory conditions.

The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, hypotension, and psychomotor impairment.

The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may exhibit somnolence, decreased respiratory rate, hypoxemia, and unresponsiveness. This can rapidly progress to life-threatening respiratory arrest.

The concurrent use of methadone and clonazepam significantly increases the risk of profound sedation, respiratory depression, coma, and death. Patients may exhibit somnolence, decreased level of consciousness, bradycardia, hypotension, and hypoventilation. This combination can also impair psychomotor function, increasing the risk of falls and accidents.

The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, pinpoint pupils, and hypotension.

The combination significantly increases the risk of profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, hypoxia, and hypotension. These effects can be rapid in onset and life-threatening.

This interaction significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, and hypotension.

Patients may experience profound sedation, respiratory depression, coma, and death. Other symptoms can include severe psychomotor impairment, hypotension, and decreased level of consciousness. The onset of these effects can be rapid and life-threatening.

The combination significantly increases the risk of severe adverse events including profound sedation, respiratory depression, coma, and death. Patients may experience extreme drowsiness, confusion, dizziness, slowed or stopped breathing, and unresponsiveness.

Concomitant use can lead to severe and potentially fatal adverse effects, including profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, bradycardia, hypotension, and diminished protective reflexes. The risk of overdose is significantly increased.

The primary clinical effects include profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, hypoxia, and hypotension. These effects can be rapid in onset and life-threatening.

The concurrent use of oxymorphone and diazepam can lead to profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, apnea, hypotension, and psychomotor impairment. This interaction significantly increases the risk of accidental overdose and life-threatening adverse events.

Concomitant use can lead to severe and potentially fatal respiratory depression, profound sedation, coma, and death. Patients may exhibit decreased level of consciousness, hypoventilation, bradycardia, hypotension, and miosis. The risk is heightened in opioid-naïve individuals, elderly patients, or those with underlying respiratory compromise.

The concurrent use of oxymorphone and temazepam significantly increases the risk of severe adverse effects, including profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, and hypotension, which can progress rapidly.

Patients may experience severe sedation, profound respiratory depression, coma, and death. Other effects can include hypotension, psychomotor impairment, and increased risk of accidental overdose.

The primary clinical effects include severe respiratory depression, profound sedation, somnolence, coma, and potentially death. Patients may exhibit decreased respiratory rate, shallow breathing, hypoxemia, hypotension, and impaired psychomotor function.

The concurrent use of oxymorphone and chlordiazepoxide significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may exhibit decreased level of consciousness, hypoventilation, pinpoint pupils, and hypotension.

This combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, and hypotension. The FDA has issued a Black Box Warning highlighting these life-threatening risks.

The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, dizziness, extreme drowsiness, slowed or difficult breathing, and hypoxemia.

The concurrent use of tapentadol and temazepam significantly increases the risk of severe respiratory depression, profound sedation, hypotension, coma, and death. Patients may experience decreased level of consciousness, slowed or shallow breathing, and psychomotor impairment.

The concurrent use of tapentadol and midazolam significantly increases the risk of severe adverse outcomes including profound sedation, respiratory depression, coma, and death. Patients may exhibit decreased level of consciousness, hypoventilation, bradycardia, and hypotension.